verapamil has been researched along with Autoimmune Diabetes in 18 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Current study aimed to appraise the potential therapeutic benefits of pharmacological inhibition of TXNIP using verapamil in diabetic retinopathy." | 8.02 | Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury. ( Eissa, LD; El-Azab, MF; Ghobashy, WA, 2021) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| " Current study aimed to appraise the potential therapeutic benefits of pharmacological inhibition of TXNIP using verapamil in diabetic retinopathy." | 4.02 | Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury. ( Eissa, LD; El-Azab, MF; Ghobashy, WA, 2021) |
| "The 2 patients with recurrences are now successfully treated with a calcium channel blocker, an approach, to our knowledge, never before reported for adult-onset nesidioblastosis." | 2.41 | Adult-onset nesidioblastosis causing hypoglycemia: an important clinical entity and continuing treatment dilemma. ( Costa, EA; Kaplan, EL; Koka, MR; Straus II, FH; Sugg, SL; Witteles, RM, 2001) |
| "Verapamil promotes functional β-cell mass and improves glucose homeostasis in diabetic mice and humans with type 1 diabetes (T1D)." | 1.91 | Verapamil Prevents Decline of IGF-I in Subjects With Type 1 Diabetes and Promotes β-Cell IGF-I Signaling. ( Chen, J; Lu, B; Qian, WJ; Sethupathy, P; Shalev, A; Xu, G, 2023) |
| "Serum from patients with IDDM increased L-type calcium channel activity of insulin-producing cells and of GH3 cells derived from a pituitary tumor." | 1.29 | Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes. ( Ammälä, C; Bokvist, K; Dypbukt, J; Hallberg, A; Juntti-Berggren, L; Larsson, O; Nicotera, P; Orrenius, S; Rorsman, P; Wåhlander, K, 1993) |
| " Forearm blood flow was determined by venous occlusion plethysmography, and dose-response curves were generated for each drug." | 1.29 | Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. ( Creager, MA; Creager, SJ; Cusco, JA; Johnstone, MT; Lee, BK; Scales, KM, 1993) |
| "Verapamil was more effective than nifedipine in improving natriuresis and ANP release to saline load and in lowering the albumin excretion rate." | 1.28 | Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. ( Abaterusso, C; Brocco, E; Carraro, A; Cipollina, MR; Fioretto, P; Frigato, F; Muollo, B; Riva, F; Trevisan, M; Velussi, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.11) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 2 (11.11) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 7 (38.89) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, G | 3 |
| Grimes, TD | 1 |
| Grayson, TB | 2 |
| Chen, J | 2 |
| Thielen, LA | 2 |
| Tse, HM | 1 |
| Li, P | 2 |
| Kanke, M | 1 |
| Lin, TT | 1 |
| Schepmoes, AA | 1 |
| Swensen, AC | 1 |
| Petyuk, VA | 1 |
| Ovalle, F | 2 |
| Sethupathy, P | 2 |
| Qian, WJ | 2 |
| Shalev, A | 3 |
| Pham, VT | 1 |
| Ciccaglione, M | 1 |
| Ramirez, DG | 1 |
| Benninger, RKP | 1 |
| Forlenza, GP | 2 |
| McVean, J | 1 |
| Beck, RW | 1 |
| Bauza, C | 1 |
| Bailey, R | 1 |
| Buckingham, B | 1 |
| DiMeglio, LA | 1 |
| Sherr, JL | 1 |
| Clements, M | 1 |
| Neyman, A | 1 |
| Evans-Molina, C | 1 |
| Sims, EK | 1 |
| Messer, LH | 1 |
| Ekhlaspour, L | 1 |
| McDonough, R | 1 |
| Van Name, M | 1 |
| Rojas, D | 1 |
| Beasley, S | 1 |
| DuBose, S | 1 |
| Kollman, C | 1 |
| Moran, A | 1 |
| Schamberger, MS | 1 |
| Buckingham, BA | 1 |
| Hsu, NC | 1 |
| Tsai, HB | 1 |
| Hsu, CH | 1 |
| Lu, B | 1 |
| Eissa, LD | 1 |
| Ghobashy, WA | 1 |
| El-Azab, MF | 1 |
| Grimes, T | 1 |
| Patel, AJ | 1 |
| Lam, TKT | 1 |
| Cherney, DZI | 1 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Juntti-Berggren, L | 1 |
| Larsson, O | 1 |
| Rorsman, P | 1 |
| Ammälä, C | 1 |
| Bokvist, K | 1 |
| Wåhlander, K | 1 |
| Nicotera, P | 1 |
| Dypbukt, J | 1 |
| Orrenius, S | 1 |
| Hallberg, A | 1 |
| Elliott, WJ | 1 |
| Johnstone, MT | 1 |
| Creager, SJ | 1 |
| Scales, KM | 1 |
| Cusco, JA | 1 |
| Lee, BK | 1 |
| Creager, MA | 1 |
| Witteles, RM | 1 |
| Straus II, FH | 1 |
| Sugg, SL | 1 |
| Koka, MR | 1 |
| Costa, EA | 1 |
| Kaplan, EL | 1 |
| Fioretto, P | 1 |
| Frigato, F | 1 |
| Velussi, M | 1 |
| Riva, F | 1 |
| Muollo, B | 1 |
| Carraro, A | 1 |
| Brocco, E | 1 |
| Cipollina, MR | 1 |
| Abaterusso, C | 1 |
| Trevisan, M | 1 |
| Calver, A | 1 |
| Collier, J | 1 |
| Vallance, P | 1 |
| Shub, C | 1 |
| Vlietstra, RE | 1 |
| McGoon, MD | 1 |
| Bruserud, O | 1 |
| Thorsby, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D)[NCT04545151] | Phase 2 | 138 participants (Anticipated) | Interventional | 2021-02-08 | Recruiting | ||
| The Effects of Watermelon Juice Supplementation on Postprandial Vascular Endothelial Function and Blood Flow During Hyperglycemia: A Pilot Study[NCT04092439] | 18 participants (Actual) | Interventional | 2019-09-12 | Completed | |||
| The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans[NCT02490124] | 7 participants (Actual) | Observational | 2014-12-31 | Completed | |||
| The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes[NCT03174288] | 32 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for verapamil and Autoimmune Diabetes
| Article | Year |
|---|---|
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Adult-onset nesidioblastosis causing hypoglycemia: an important clinical entity and continuing treatment dilemma.
Topics: Adult; Age of Onset; Calcium Channel Blockers; Combined Modality Therapy; Diabetes Mellitus, Type 1; | 2001 |
Selection of optimal drug therapy for the patient with angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Calcium Channel | 1985 |
1 trial available for verapamil and Autoimmune Diabetes
| Article | Year |
|---|---|
Verapamil and beta cell function in adults with recent-onset type 1 diabetes.
Topics: Adult; Blood Pressure; Diabetes Mellitus, Type 1; Heart Rate; Humans; Insulin; Insulin-Secreting Cel | 2018 |
14 other studies available for verapamil and Autoimmune Diabetes
| Article | Year |
|---|---|
Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes.
Topics: Diabetes Mellitus, Type 1; Humans; Immunologic Factors; Immunotherapy; Insulin; Verapamil | 2022 |
Ultrasound Imaging of Pancreatic Perfusion Dynamics Predicts Therapeutic Prevention of Diabetes in Preclinical Models of Type 1 Diabetes.
Topics: Animals; Diabetes Mellitus, Type 1; Islets of Langerhans; Mice; Mice, Inbred NOD; Mice, SCID; Pancre | 2022 |
Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial.
Topics: Adolescent; C-Peptide; Child; Diabetes Mellitus, Type 1; Double-Blind Method; Female; Humans; Hypogl | 2023 |
Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes-Reply.
Topics: Calcium Channel Blockers; Child; Diabetes Mellitus, Type 1; Humans; Insulin-Secreting Cells; Verapam | 2023 |
Verapamil and Pancreatic Beta Cell Function in Pediatric Type 1 Diabetes.
Topics: Calcium Channel Blockers; Child; Diabetes Mellitus, Type 1; Humans; Insulin-Secreting Cells; Verapam | 2023 |
Verapamil Prevents Decline of IGF-I in Subjects With Type 1 Diabetes and Promotes β-Cell IGF-I Signaling.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucose; Humans; Insulin-Like G | 2023 |
Inhibition of thioredoxin-interacting protein and inflammasome assembly using verapamil mitigates diabetic retinopathy and pancreatic injury.
Topics: Angiogenesis Inhibitors; Animals; Blood Glucose; Calcium Channel Blockers; Cell Cycle Proteins; Diab | 2021 |
Beta cell preservation in patients with type 1 diabetes.
Topics: Adult; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Insulin-Secreting Cells; Verapa | 2018 |
Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1993 |
An individualized approach to the hypertensive patient with renal disease: six illustrative case studies.
Topics: Adrenergic alpha-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Arterial Occlusive Dis | 1995 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus.
Topics: Adult; Blood Flow Velocity; Blood Glucose; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Endothe | 1993 |
Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients.
Topics: Adult; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Calcium Cha | 1992 |
Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes.
Topics: Acetylcholine; Adult; Arginine; Arm; Diabetes Mellitus, Type 1; Humans; Male; Nitric Oxide; Nitropru | 1992 |
T lymphocyte responses to Coxsackie B4 and mumps virus. I. Influence of HLA-DR restriction elements.
Topics: Aminophylline; Antigens, Viral; Diabetes Mellitus, Type 1; Enterovirus; Herpesvirus 3, Human; Histoc | 1985 |